Mark Slabaugh, MD
Glaucoma Specialist · Columbus, OHNPI 1669583597
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $3,000 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Bausch & Lomb, A Division Of Bausch Health US, LLC.
Across 3 payments — averaging $1000.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
Across 73 payments — averaging $3249.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$237K
What the payments were for
- Speaking & faculty fees$3,000100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $3,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROLENSA$3,000
- LOTEMAX$3,000
- CRYSTALENS$3,000
- ENVISTA$3,000
- VICTUS$3,000
How this compares
Too few glaucoma specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 65 | $28,062 |
| RestasisCyclosporine | 27 | $25,042 |
| Prednisolone Acetate | 522 | $18,090 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $9,989 |
| Latanoprost | 871 | $7,343 |
| Brinzolamide | 19 | $5,575 |
| Travoprost | 44 | $5,021 |
| Brimonidine Tartrate | 149 | $4,865 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 358 | $4,857 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 30 | $4,730 |
| Fluorometholone | 68 | $4,186 |
| Timolol Maleate | 302 | $3,026 |
| Ketorolac Tromethamine | 196 | $2,192 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,686 |
| Acetazolamide | 22 | $1,298 |
Paid to pharmacies, not to this prescriber.
Other glaucoma specialist in Columbus
- Shelly JainColumbus$11K
- Gloria FlemingColumbus$2K
- Emily RossColumbus$1K
- Paul WeberColumbus$47
- Sayoko MoroiColumbus$28
- Mary QiuCleveland$99K
- Stephan DixonCincinnati$82K
- Shalini SoodIndependence$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.